RESUMEN
Cisplatin is one of the most common drugs used for treatment of solid tumors such as ovarian cancer. Unfortunately, the development of resistance against this cytotoxic agent limits its clinical use. Here we report that YSY01A, a novel proteasome inhibitor, is capable of suppressing survival of cisplatin-resistant ovarian cancer cells by inducing apoptosis. And YSY01A treatment enhances the cytotoxicity of cisplatin in drug-resistant ovarian cancer cells. Specifically, YSY01A abrogates regulatory proteins important for cell proliferation and anti-apoptosis including NF-κB p65 and STAT3, resulting in down-regulation of Bcl-2. A dramatic increase in cisplatin uptake was also observed by inductively coupled plasma-mass spectrometry following exposure to YSY01A. Taken together, YSY01A serves as a potential candidate for further development as anticancer therapeutics targeting the proteasome.
RESUMEN
OBJECTIVE: To investigate the expression of UNC-112 protein in lung cancer and discuss its value. METHODS: The method of immunohistochemical SP was employed to detect the expression of UNC-112 protein in 210 cases of lung cancer, and evaluate its correlation with pathological classification. RESULTS: UNC-112A and UNC-112B protein were highly expressed in non-small cell lung cancer, not expressed or expressed at very low levels in small cell lung cancer(P < 0.05);the expression of UNC-112A protein in squamous cell carcinoma was significantly higher than those in adenocarcinoma (P < 0.001)and large cell lung cancer (P < 0.01), but there is no significant difference between adenocarcinoma and large cell lung cancer (P = 0.18).UNC-112A protein expression level was positively correlated with the differentiation of squamous cell carcinoma(P = 0.0024). The expression of UNC-112B protein was significantly higher in large cell lung cancer than those in adenocarcinoma (P = 0.002) and squamous cell carcinoma (P < 0.01), and it was significantly higher in adenocarcinoma than squamous cell carcinoma (P = 0.005). CONCLUSIONS: UNC-112 protein may be related to the heterogeneity of lung cancer, UNC-112A and UNC-112B protein play different roles in invasion and migration of lung cancer.